Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
TAK 
Takeda Pharmaceutical Co Ltd ADR (TAK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/01/2025: TAK (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $17.52
1 Year Target Price $17.52
| 3 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -17.92% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/01/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 48.12B USD | Price to earnings Ratio 206.57 | 1Y Target Price 17.52 |
Price to earnings Ratio 206.57 | 1Y Target Price 17.52 | ||
Volume (30-day avg) 4 | Beta 0.03 | 52 Weeks Range 12.24 - 15.35 | Updated Date 12/2/2025 |
52 Weeks Range 12.24 - 15.35 | Updated Date 12/2/2025 | ||
Dividends yield (FY) 4.60% | Basic EPS (TTM) 0.07 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 0.75% | Operating Margin (TTM) 15.29% |
Management Effectiveness
Return on Assets (TTM) 2.09% | Return on Equity (TTM) 0.47% |
Valuation
Trailing PE 206.57 | Forward PE 9.58 | Enterprise Value 70524706520 | Price to Sales(TTM) 0.01 |
Enterprise Value 70524706520 | Price to Sales(TTM) 0.01 | ||
Enterprise Value to Revenue 2.5 | Enterprise Value to EBITDA 10.59 | Shares Outstanding 3159188548 | Shares Floating 1578535946 |
Shares Outstanding 3159188548 | Shares Floating 1578535946 | ||
Percent Insiders 0.01 | Percent Institutions 2.72 |
Upturn AI SWOT
Takeda Pharmaceutical Co Ltd ADR
Company Overview
History and Background
Takeda Pharmaceutical Co. Ltd. was founded in 1781 in Osaka, Japan. Initially a medicine wholesaler, it evolved into a research-based pharmaceutical company. Key milestones include expansion into global markets, strategic acquisitions, and a focus on innovative therapies.
Core Business Areas
- Gastroenterology: Focuses on treatments for gastrointestinal disorders like inflammatory bowel disease.
- Rare Diseases: Develops therapies for rare genetic and acquired diseases.
- Plasma-Derived Therapies: Produces plasma-derived products for immune deficiencies and other conditions.
- Oncology: Develops treatments for various cancers.
- Neuroscience: Focuses on treatments for neurological and psychiatric disorders, including ADHD and depression.
Leadership and Structure
The leadership team includes the CEO and various executive officers overseeing different business units and functions. The organizational structure is a global matrix, balancing regional operations with global product divisions.
Top Products and Market Share
Key Offerings
- Entyvio: A biologic therapy for ulcerative colitis and Crohn's disease. Competitors include Humira (ABBV), Remicade (JNJ), and Stelara (JNJ). It is estimated to generate billions of dollars in revenue annually.
- Vyvanse/Elvanse: A treatment for ADHD. Competitors include Adderall (Generic), Ritalin (Generic), and Concerta (JNJ). Competitors compete in the market, Takedau2019s market share is substantial. There is approximately $2.5 Billion in revenues yearly.
- Livtencity: A treatment for post-transplant cytomegalovirus (CMV). Competitors are Prevemis (MRK). Livtencity is approved to treat adults and children 12 years of age and older with CMV infection that has returned or has not improved.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, regulatory scrutiny, and patent expirations. It's a global market with increasing demand for innovative therapies and personalized medicine.
Positioning
Takeda is a global, values-based, R&D-driven biopharmaceutical leader committed to discovering and delivering life-transforming treatments, guided by our commitment to patients, our people and the planet.
Total Addressable Market (TAM)
The global pharmaceutical market is estimated to be worth over $1.4 trillion and is expected to continue growing. Takeda has positioned itself within this TAM by investing in innovative technologies and focusing on key therapeutic areas.
Upturn SWOT Analysis
Strengths
- Strong R&D pipeline
- Global presence and distribution network
- Focus on innovative therapies
- Expertise in specialty therapeutic areas
Weaknesses
- High debt levels
- Reliance on key products
- Exposure to patent expirations
- Integration challenges from acquisitions
Opportunities
- Expanding into emerging markets
- Developing new therapies for unmet medical needs
- Leveraging digital health technologies
- Strategic partnerships and collaborations
Threats
- Generic competition
- Regulatory changes
- Pricing pressures
- Economic downturns
Competitors and Market Share
Key Competitors
- JNJ
- MRK
- ABBV
- NVS
- PFE
Competitive Landscape
Takeda competes with major pharmaceutical companies. Its advantage includes focus and specialization. It should keep up with pricing.
Major Acquisitions
Shire
- Year: 2019
- Acquisition Price (USD millions): 62000
- Strategic Rationale: Expanded Takeda's pipeline, particularly in rare diseases.
Growth Trajectory and Initiatives
Historical Growth: Takeda has experienced growth through organic initiatives, as well as acquisitions.
Future Projections: Analysts expect Takeda to experience continued growth in the future.
Recent Initiatives: Takeda is focusing on its R&D pipeline and strategic partnerships to drive future growth.
Summary
Takeda is a global pharmaceutical company with a strong focus on R&D and key therapeutic areas. It has demonstrated significant growth through acquisitions. The company faces challenges related to generic competition and pricing pressures. Its future success hinges on its ability to innovate and capitalize on emerging market opportunities.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry News
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Takeda Pharmaceutical Co Ltd ADR
Exchange NYSE | Headquaters - | ||
IPO Launch date 2008-10-27 | President, CEO & Representative Director Mr. Christophe Weber | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 47455 | Website https://www.takeda.com |
Full time employees 47455 | Website https://www.takeda.com | ||
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.